Literature DB >> 8589724

Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm.

B J Longley1, L Tyrrell, S Z Lu, Y S Ma, K Langley, T G Ding, T Duffy, P Jacobs, L H Tang, I Modlin.   

Abstract

Mastocytosis is characterized by accumulations of mast cells in various organs (1). Most cases are indolent and confined to the skin, where discrete mast cell infiltrates are associated increased epidermal melanin, a clinical picture known as urticaria pigmentosa (UP). Other forms of mastocytosis combine UP with aggressive involvement of other organs or with haemotologic abnormalities (1-4). It is not known whether all forms of mastocytosis are true neoplasms or whether some might represent reactive hyperplasias (5-7). The c-KIT proto-oncogene encodes a type III receptor tyrosine kinase (KIT) that is critical to the development and survival of mast cells and melanocytes (8-11). The ligand for KIT (KL) can stimulate mast cell development, proliferation, and mediator release (9,12-17), as well as melanocyte proliferation and pigment production (18-20). To determine the role of c-KIT in the pathogenesis of mastocytosis, we examined tissue and cells isolated from a patient with UP and aggressive systemic mastocytosis with massive splenic involvement. We found a mutation that results in constitutive activation and expression of c-KIT in mast cells of both skin and spleen. This is the first in situ demonstration of an activation c-KIT mutation in neoplastic cells. It also demonstrates the clonal and neoplastic nature of this form of mastocytes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8589724     DOI: 10.1038/ng0396-312

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  112 in total

1.  Increased angiogenesis in the bone marrow of patients with systemic mastocytosis.

Authors:  Friedrich Wimazal; John-Hendrik Jordan; Wolfgang R Sperr; Andreas Chott; Sana Dabbass; Klaus Lechner; Hans P Horny; Peter Valent
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

2.  One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes.

Authors:  Karl Sotlar; Luis Escribano; Olfert Landt; Stefanie Möhrle; Sonia Herrero; Antonio Torrelo; Ulrich Lass; Hans-Peter Horny; Burkhard Bültmann
Journal:  Am J Pathol       Date:  2003-03       Impact factor: 4.307

3.  Chymase cleavage of stem cell factor yields a bioactive, soluble product.

Authors:  B J Longley; L Tyrrell; Y Ma; D A Williams; R Halaban; K Langley; H S Lu; N M Schechter
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

Review 4.  Molecular biology of adenoid cystic carcinoma.

Authors:  Jia Liu; Chunbo Shao; Marietta L Tan; David Mu; Robert L Ferris; Patrick K Ha
Journal:  Head Neck       Date:  2011-10-17       Impact factor: 3.147

5.  Hematopoietic stem-cell transplantation for advanced systemic mastocytosis.

Authors:  Celalettin Ustun; Andreas Reiter; Bart L Scott; Ryotaro Nakamura; Gandhi Damaj; Sebastian Kreil; Ryan Shanley; William J Hogan; Miguel-Angel Perales; Tsiporah Shore; Herrad Baurmann; Robert Stuart; Bernd Gruhn; Michael Doubek; Jack W Hsu; Eleni Tholouli; Tanja Gromke; Lucy A Godley; Livio Pagano; Andrew Gilman; Eva Maria Wagner; Tor Shwayder; Martin Bornhäuser; Esperanza B Papadopoulos; Alexandra Böhm; Gregory Vercellotti; Maria Teresa Van Lint; Christoph Schmid; Werner Rabitsch; Vinod Pullarkat; Faezeh Legrand; Ibrahim Yakoub-Agha; Wael Saber; John Barrett; Olivier Hermine; Hans Hagglund; Wolfgang R Sperr; Uday Popat; Edwin P Alyea; Steven Devine; H Joachim Deeg; Daniel Weisdorf; Cem Akin; Peter Valent
Journal:  J Clin Oncol       Date:  2014-08-25       Impact factor: 44.544

6.  "Occult" mastocytosis with activating c-kit point mutation evolving into systemic mastocytosis associated with plasma cell myeloma and secondary amyloidosis.

Authors:  K Sotlar; W Saeger; F Stellmacher; J Stahmer; S Jäckle; P Valent; H-P Horny
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

7.  Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias.

Authors:  Wanlong Ma; Hagop Kantarjian; Xi Zhang; Chen-Hsiung Yeh; Zhong J Zhang; Srdan Verstovsek; Maher Albitar
Journal:  J Mol Diagn       Date:  2008-12-12       Impact factor: 5.568

8.  Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis.

Authors:  B J Longley; D D Metcalfe; M Tharp; X Wang; L Tyrrell; S Z Lu; D Heitjan; Y Ma
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

9.  FIP1L1-PDGFRalpha imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells.

Authors:  Kentaro Fukushima; Itaru Matsumura; Sachiko Ezoe; Masahiro Tokunaga; Masato Yasumi; Yusuke Satoh; Hirohiko Shibayama; Hirokazu Tanaka; Atsushi Iwama; Yuzuru Kanakura
Journal:  J Biol Chem       Date:  2009-01-14       Impact factor: 5.157

10.  Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth.

Authors:  A Bardelli; P Longati; D Gramaglia; C Basilico; L Tamagnone; S Giordano; D Ballinari; P Michieli; P M Comoglio
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.